Dr. Gasparetto on Selinexor and Daratumumab Combination in Multiple Myeloma

Cristina Gasparetto, MD
Published: Tuesday, Dec 19, 2017



Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses a phase Ib study of the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma.

There are preliminary data demonstrating that selinexor resensitizes the myeloma cells to daratumumab, Gasparetto says.

This study was attempting to determine the dose of the combination. In the first cohort selinexor and daratumumab was given 60 mg/kg twice a week, explains Gasparetto.
 


Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses a phase Ib study of the combination of selinexor and daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma.

There are preliminary data demonstrating that selinexor resensitizes the myeloma cells to daratumumab, Gasparetto says.

This study was attempting to determine the dose of the combination. In the first cohort selinexor and daratumumab was given 60 mg/kg twice a week, explains Gasparetto.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x